The status of these different areas is that Metis health benefit qualification was reviewed at the end of 2022 to enable more people to participate. That work is complete. The medical travel was reviewed, and a number of changes were suggested, and that review is complete. The extended health benefits are being reviewed on a phased basis, and so the most recent initiative in this area is the biosimilar initiative, or as they're more commonly called generics. So we are asking patients and doctors to switch to biosimilars, to have those conversations over the next -- I guess there's about four months left in this period now. Over the next four months to look at switching people from biologic drugs to biosimilar drugs. There are more changes planned in this area but they're being phased in over time. Thank you.
Julie Green on Consideration In Committee Of The Whole Of Bills And Other Matters
In the Legislative Assembly on March 9th, 2022. See this statement in context.
Consideration In Committee Of The Whole Of Bills And Other Matters
Consideration In Committee Of The Whole Of Bills And Other Matters
March 9th, 2022
Page 3918
See context to find out what was said next.